Pulse Biosciences (NASDAQ:PLSE) Trading Up 6.5%

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares shot up 6.5% on Wednesday . The stock traded as high as $12.37 and last traded at $12.15. 48,975 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 204,195 shares. The stock had previously closed at $11.41.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, June 27th.

Pulse Biosciences Trading Up 1.1 %

The business has a fifty day moving average price of $10.42 and a 200 day moving average price of $9.59.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the acquisition, the chief executive officer now owns 10,000 shares in the company, valued at $85,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several large investors have recently added to or reduced their stakes in PLSE. Vanguard Group Inc. increased its holdings in Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares in the last quarter. Griffin Asset Management Inc. increased its holdings in Pulse Biosciences by 15.7% in the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after purchasing an additional 40,700 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in Pulse Biosciences in the 4th quarter valued at $242,000. Cetera Advisors LLC purchased a new position in Pulse Biosciences in the 1st quarter valued at about $109,000. Finally, Inspire Investing LLC boosted its position in Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after buying an additional 10,039 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.